Biotech Stocks on Investors' Radar -- Northwest Biotherapeutics, ACADIA Pharma, Acorda Therapeutics, and Ultragenyx Pharma

NEW YORK, December 5, 2016 /PRNewswire/ --

The U.S. Biotechnology industry is the leading Biotech player worldwide, with almost $108 billion of revenue and some $890 billion of total market value. In 2013, around $170 billion were spent on global biopharmaceuticals, and this figure is expected to exceed $220 billion by 2017. This morning, Stock-Callers.com has lined up these four equities for assessment: Northwest Biotherapeutics Inc. (NASDAQ: NWBO), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Acorda Therapeutics Inc. (NASDAQ: ACOR), and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). Learn more about these stocks by downloading their comprehensive and free reports at:

http://stock-callers.com/registration

Northwest Biotherapeutics  

Bethesda, Maryland headquartered Northwest Biotherapeutics Inc.'s shares finished Friday's session 1.99% higher at $0.49. A total volume of 983,161 shares was traded. The stock has gained 10.68% in the last month and 43.19% in the previous three months. The Company's shares are trading below their 50-day moving average by 0.74%. Moreover, shares of Northwest Biotherapeutics, which discovers and develops immunotherapy products to treat cancer in the US and internationally, have a Relative Strength Index (RSI) of 50.04.

On November 17^th, 2016, Northwest Biotherapeutics joined the University Medical Center (UMC) of the Johannes Gutenberg University Mainz in Germany in announcing a Phase II clinical trial program combining DCVax®-L and Pembrolizumab (Keytruda®) for colorectal cancer with liver metastases. The trial will be conducted as an investigator-initiated trial led by the University of Mainz, thereby substantially reducing the costs involved.  Northwest Biotherapeutics will provide the DCVax-L products and MSD Sharp & Dohme GmbH will provide the Pembrolizumab. (MSD Sharp & Dohme is the operating name used by U.S.-based Merck & Co., Inc. outside the U.S. and Canada). NWBO complete research report is just a click away and free at:

http://stock-callers.com/registration/?symbol=NWBO

ACADIA Pharma  

Shares in San Diego, California headquartered ACADIA Pharmaceuticals Inc. ended the day 2.53% higher at $27.15 with a total trading volume of 1.51 million shares. The stock has advanced 23.41% in the last month. The Company's shares are trading 0.12% below their 50-day moving average. Moreover, shares of ACADIA Pharma, which focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders, have an RSI of 49.50.

On November 11^th, 2016, research firm Goldman initiated a 'Neutral' rating on the Company's stock.

On December 01^st, 2016, ACADIA Pharmaceuticals announced the initiation of CLARITY, a Phase II study to evaluate pimavanserin for adjunctive treatment in patients with major depressive disorder (MDD) who have an inadequate response to first-line therapies for clinical depression. Pimavanserin is a selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors that may play a role in depression. The complimentary report on ACAD can be downloaded at:

http://stock-callers.com/registration/?symbol=ACAD

Acorda Therapeutics  

Ardsley, New York headquartered Acorda Therapeutics Inc.'s stock rose 0.25%, closing the session at $20.30. A total volume of 434,733 shares was traded. The Company's shares have gained 15.67% in the last one month. The stock is trading 0.03% above its 50-day moving average. Additionally, shares of Acorda Therapeutics, which identifies, develops, and commercializes novel therapies for neurological disorders in the US, have an RSI of 50.18.

On November 21^st, 2016, Acorda Therapeutics announced that the MILESTONE clinical study did not show sufficient efficacy to support further development of dalfampridine to improve post-stroke walking difficulties. The Company elected to stop enrollment and to conduct an unblinded analysis of the MILESTONE trial after reaching enrollment of 377 participants. The primary outcome measure of the study was the proportion of participants who showed at least a 20% improvement on the Two Minute Walk Test (2MinWT) at Week 12 as compared to baseline.

On November 30^th, 2016, research firm JP Morgan upgraded the Company's stock rating from 'Neutral' to 'Overweight'. Sign up for your complimentary research report on ACOR at:

http://stock-callers.com/registration/?symbol=ACOR

Ultragenyx Pharma  

On Friday, shares in Novato, California headquartered Ultragenyx Pharmaceutical Inc. finished the session 0.19% lower at $74.55. A total volume of 518,474 shares was traded. The stock has gained 28.45% in the last month and 14.46% over the previous three months. The Company's shares are trading above their 50-day and 200-day moving averages by 5.70% and 14.72%, respectively. Furthermore, shares of Ultragenyx Pharma, which focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the US, have an RSI of 47.96.

On November 14^th, 2016, research firm Citigroup downgraded the Company's stock rating from 'Neutral' to 'Sell'.

On November 30^th, 2016, Ultragenyx Pharmaceutical announced positive 78-week data from the Phase 2 study of UX007 (triheptanoin) in patients with long-chain fatty acid oxidation disorder. The frequency and duration of major medical events were reduced significantly during treatment with UX007, and patients demonstrated improved exercise tolerance and quality of life during the study. Get free access to your research report on RARE at:

http://stock-callers.com/registration/?symbol=RARE

--

Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

http://stock-callers.com/legal-disclaimer/

CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@stock-callers.com
Phone number:  +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA